These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33636308)

  • 1. Oxa-adamantyl cannabinoids.
    Ho TC; Tius MA; Nikas SP; Tran NK; Tong F; Zhou H; Zvonok N; Makriyannis A
    Bioorg Med Chem Lett; 2021 Apr; 38():127882. PubMed ID: 33636308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors.
    Noble C; Cannaert A; Linnet K; Stove CP
    Drug Test Anal; 2019 Mar; 11(3):501-511. PubMed ID: 30280499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel class of selective human CB1 inverse agonists.
    Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-functionalized adamantyl cannabinoid receptor probes.
    Ogawa G; Tius MA; Zhou H; Nikas SP; Halikhedkar A; Mallipeddi S; Makriyannis A
    J Med Chem; 2015 Apr; 58(7):3104-16. PubMed ID: 25760146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel adamantyl cannabinoids as CB1 receptor probes.
    Thakur GA; Bajaj S; Paronis C; Peng Y; Bowman AL; Barak LS; Caron MG; Parrish D; Deschamps JR; Makriyannis A
    J Med Chem; 2013 May; 56(10):3904-21. PubMed ID: 23621789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adamantyl cannabinoids: a novel class of cannabinergic ligands.
    Lu D; Meng Z; Thakur GA; Fan P; Steed J; Tartal CL; Hurst DP; Reggio PH; Deschamps JR; Parrish DA; George C; Järbe TU; Lamb RJ; Makriyannis A
    J Med Chem; 2005 Jul; 48(14):4576-85. PubMed ID: 15999995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes.
    Le Goanvic D; Tius MA
    J Org Chem; 2006 Sep; 71(20):7800-4. PubMed ID: 16995689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
    Ashton JC; Wright JL; McPartland JM; Tyndall JD
    Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mastering tricyclic ring systems for desirable functional cannabinoid activity.
    Petrov RR; Knight L; Chen SR; Wager-Miller J; McDaniel SW; Diaz F; Barth F; Pan HL; Mackie K; Cavasotto CN; Diaz P
    Eur J Med Chem; 2013 Nov; 69():881-907. PubMed ID: 24125850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
    Huffman JW; Szklennik PV; Almond A; Bushell K; Selley DE; He H; Cassidy MP; Wiley JL; Martin BR
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4110-3. PubMed ID: 16005223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
    Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
    Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biological effects and thermal degradation of NPB-22, a synthetic cannabinoid.
    Takeda A; Doi T; Asada A; Yuzawa K; Nagasawa A; Igarashi K; Maeno T; Suzuki A; Shimizu S; Uemura N; Nakajima J; Suzuki T; Inomata A; Tagami T
    Forensic Toxicol; 2024 Jul; 42(2):142-151. PubMed ID: 38294576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled-deactivation cannabinergic ligands.
    Sharma R; Nikas SP; Paronis CA; Wood JT; Halikhedkar A; Guo JJ; Thakur GA; Kulkarni S; Benchama O; Raghav JG; Gifford RS; Järbe TU; Bergman J; Makriyannis A
    J Med Chem; 2013 Dec; 56(24):10142-57. PubMed ID: 24286207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs.
    Deventer MH; Persson M; Norman C; Liu H; Connolly MJ; Daéid NN; McKenzie C; Gréen H; Stove CP
    Drug Test Anal; 2024 Jun; 16(6):616-628. PubMed ID: 37903509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to develop selective CB
    Moir M; Lane S; Lai F; Connor M; Hibbs DE; Kassiou M
    Eur J Med Chem; 2019 Oct; 180():291-309. PubMed ID: 31319265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor.
    Alapafuja SO; Nikas SP; Ho TC; Tong F; Benchama O; Makriyannis A
    Molecules; 2019 Oct; 24(19):. PubMed ID: 31581433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.